Core Viewpoint - The acquisition plan by Kanglong Chemical (康龙化成) to purchase 82.54% of Wuxi Baiaode Bio-Science Co., Ltd. for approximately 1.346 billion yuan has raised market concerns regarding the high premium and financial pressure on the company [1][4][7]. Group 1: Acquisition Details - Kanglong Chemical aims to enhance its technological platform and implement its core strategy of "full-process, integrated, international, and multi-therapy" through this acquisition [2][8]. - The acquisition price represents a significant premium, valuing Baiaode at approximately 1.631 billion yuan, which is an increase of 168.21% over its net assets [7]. - The valuation of Baiaode has been supported by previous market financing rounds, with post-investment valuations reaching approximately 1.57 billion yuan in 2021 and 2.57 billion yuan in 2023 [7]. Group 2: Financial Performance - For the first three quarters of 2025, Kanglong Chemical reported a revenue of 10.086 billion yuan, marking a record high, but its net profit attributable to shareholders decreased by 19.76% [5][15]. - As of September 2025, the company had interest-bearing liabilities of approximately 6 billion yuan, with financial expenses exceeding 150 million yuan for the first three quarters [4][11]. Group 3: Market Reaction and Shareholder Actions - The stock price of Kanglong Chemical has seen a significant decline, closing at 29 yuan per share on November 24, 2025, down over 70% from its peak of 244.60 yuan per share in August 2021 [6][15]. - Major shareholders have been actively reducing their stakes, with significant cash-outs totaling around 12 billion yuan since 2022 [14][15].

Core Insights - The report highlights significant changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies [1][2][3] Group 1: Increased Holdings - The companies with the largest increases in Hong Kong Stock Connect holdings include: - Hang Seng China Enterprises (02828) with an increase of 6.14%, bringing the latest holding percentage to 6.97% [2] - Tracker Fund of Hong Kong (02800) with an increase of 4.94%, resulting in a holding percentage of 7.09% [2] - Southern Hang Seng Technology (03033) with an increase of 1.25%, now holding 63.41% [2] - Over the last five trading days, the top gainers in holdings were: - Guofu Hydrogen Energy (02582) with a 9.18% increase, now at 16.55% [3] - Hang Seng China Enterprises (02828) with a 6.40% increase [3] - Tracker Fund of Hong Kong (02800) with a 6.31% increase [3] Group 2: Decreased Holdings - The companies with the largest decreases in Hong Kong Stock Connect holdings include: - Shandong Molong (00568) with a decrease of 1.52%, now at 57.43% [2] - Kintor Pharmaceutical (09939) with a decrease of 1.18%, now at 17.64% [2] - Tigermed (03347) with a decrease of 1.00%, now at 46.11% [2] - Over the last five trading days, the top decliners in holdings were: - Shandong Molong (00568) with a 3.24% decrease [3] - Kintor Pharmaceutical (09939) with a 1.18% decrease [3] - Tigermed (03347) with a 1.39% decrease [3] Group 3: Long-term Trends - Over the last 20 trading days, the companies with the largest increases in holdings included: - Haotian International Construction Investment (01341) with a 17.61% increase, now at 68.76% [4] - Qingdao Bank (03866) with an 11.32% increase, now at 18.70% [4] - Guofu Hydrogen Energy (02582) with a 10.61% increase [4] - The companies with the largest decreases in holdings over the last 20 trading days included: - Xintian Green Energy (00956) with an 8.04% decrease, now at 57.35% [4] - Zhongze Feng (01282) with a 7.51% decrease, now at 8.56% [4] - Delin Holdings (01709) with a 4.52% decrease, now at 30.02% [4]

Core Viewpoint - The acquisition plan by Kanglong Chemical (康龙化成) to purchase 82.54% of Wuxi Baiaode Biological Science Co., Ltd. for approximately 1.346 billion yuan has raised market skepticism due to financial pressures and high premium valuation [1][3]. Group 1: Acquisition Details - Kanglong Chemical plans to acquire 82.54% of Baiaode for 1.346 billion yuan, aiming to enhance its "full-process, integrated, international, and multi-therapy" strategy [1][3]. - The acquisition price reflects a significant premium, valuing Baiaode at approximately 1.631 billion yuan, which is a 168.21% increase over its net assets [3]. - The valuation of Baiaode at 1.5 billion yuan was deemed reasonable by Kanglong, supported by previous market financing rounds [3]. Group 2: Financial Performance - As of September 2025, Kanglong Chemical reported total liabilities of approximately 6 billion yuan and financial expenses of 153 million yuan for the first three quarters of 2025 [2][7]. - The company achieved a record revenue of 10.086 billion yuan in the first three quarters of 2025, but its net profit decreased by 19.76% year-on-year [2][11]. Group 3: Market Reactions and Concerns - The acquisition has raised concerns about related party transactions, as approximately 500 million yuan will be cashed out by related parties through this deal [2][8]. - Kanglong's stock price has significantly declined, dropping over 70% from its peak in August 2021, closing at 29 yuan per share on November 24, 2025 [2][11]. - There has been a notable trend of major shareholders reducing their stakes, with significant cash-outs totaling around 12 billion yuan since 2022 [10][11].

Group 1 - CRO concept stocks have collectively rebounded, indicating a positive trend in the sector [1] - Tigermed (03347.HK) increased by 9.19%, reaching HKD 39.92 [1] - WuXi AppTec (02359.HK) rose by 4.43%, trading at HKD 106 [1] - Kanglong Chemical (03759.HK) saw a 4.15% increase, priced at HKD 21.58 [1] - WuXi Biologics (02269.HK) experienced a 3.27% rise, with a price of HKD 31.56 [1]

Group 1 - The CRO sector is experiencing a collective rebound, with notable stock price increases for companies such as Tigermed (up 9.19% to HKD 39.92), WuXi AppTec (up 4.43% to HKD 106), and others [1] - Citing a recovery in capital market financing activities and an expansion in the overseas trading scale of innovative drugs, the outlook for CXO companies' performance in the second half of the year is optimistic [1] - Morgan Stanley notes that since mid-September, healthcare stocks have been under pressure as investors take profits, but the fundamentals for WuXi's companies remain strong, making their valuations more attractive [1] Group 2 - WuXi AppTec is highlighted as a top pick due to its raised earnings guidance and significant capacity expansion, particularly in the next-generation GLP-1 sector [1] - The projected compound annual growth rates for WuXi AppTec, WuXi Biologics, and WuXi AppTec's subsidiary from 2024 to 2027 are 24%, 23%, and 37% respectively [1]

Group 1 - CRO concept stocks have collectively rebounded, with notable increases in share prices: Tigermed (300347) up 9.19% to HKD 39.92, WuXi AppTec (603259) up 4.43% to HKD 106, and others showing similar gains [1] - CMB International believes that the recovery of capital market financing activities, expansion of overseas transactions for innovative drugs, and a rebound in domestic R&D demand will lead to a recovery in CXO companies' performance in the second half of the year [1] - Morgan Stanley reports that healthcare stocks have been sold off since mid-September, with investors taking profits while awaiting signals for next year's performance [1] Group 2 - Morgan Stanley highlights that WuXi AppTec's fundamentals remain strong, making its valuation more attractive, especially as the company has raised its earnings guidance and is expanding capacity significantly [1] - The projected compound annual growth rates for earnings from WuXi AppTec, WuXi Biologics, and WuXi AppTec's subsidiaries from 2024 to 2027 are 24%, 23%, and 37% respectively [1]

Core Insights - The CXO sector in A-shares has shown resilience, with 20 out of 29 listed companies reporting year-on-year revenue growth in the first three quarters [1] - The growth in the CXO sector is driven by internationalization and increased demand for innovative drugs, benefiting companies in the upstream of the innovative drug industry chain [1] - The innovative drug sector is experiencing a dual boost from policy support and surging demand, which is stimulating new drug research and development [1] Summary by Categories Industry Trends - Three major trends are emerging in the innovative drug field: 1. Deepening internationalization with an expected 103 license-out transactions and upfront payments reaching $8.45 billion by 2025, leading to valuation premiums for companies going abroad [2] 2. Unprecedented policy support, including improved efficiency in medical insurance negotiations and the establishment of a directory for innovative drugs under commercial insurance for the first time [2] 3. Continuous technological breakthroughs in areas such as ADC, IO dual antibodies, GLP-1 weight loss drugs, and small nucleic acid drugs [2] Market Outlook - The CXO industry adjustment is largely complete, with stable overseas demand and a rebound in domestic investment and financing [2] - There is significant recovery in the upstream industry chain, with ample room for increasing domestic production rates, driven by smart, digital production and international expansion [2] Key Companies - Leading companies in the CXO sector include: - Kelaiying (002821) (06821) - Kanglong Chemical (300759) (03759) - Zhaoyan New Drug (603127) (06127) - WuXi Biologics (02269) - WuXi AppTec (603259) (02359) [3]

Summary of Key Points from Conference Call Records Industry Overview - The pharmaceutical industry is generally optimistic, with signs of a rebound in the innovative drug sector. Large-cap companies have seen declines of over 30%, while small-cap companies have dropped more than 50%, indicating a potential opportunity for stock alpha in the coming year [1][2][4]. Key Companies to Watch - **Innovative Drug Sector**: Focus on companies like Innovent Biologics and China National Pharmaceutical Group, as well as smaller firms like Genscript Biotech and Luyin Pharmaceutical [1][4]. - **Medical Devices**: Companies such as Mindray and Spring Medical are highlighted for their recovery and growth potential in high-value consumables and medical equipment [5][6]. - **Traditional Chinese Medicine**: Increased institutional interest, with companies like Yiling Pharmaceutical and China Resources Sanjiu expected to benefit from a recovery in the sector [1][7][9]. - **CRO and API Sectors**: Kanglong Chemical and ProPharma are noted for their growth potential, particularly in clinical research and API business recovery [1][10][11]. Market Trends and Opportunities - **High-Value Consumables**: The pressure from centralized procurement is easing, leading to a reassessment of value driven by innovation [5][6]. - **Blood Products**: The sector is in an adjustment phase but shows signs of reversal, with supply tightening expected in 2026 [3][12][15][16]. - **Oral Peptide Drugs**: New oral formulations like Merck's MK0,616 and Johnson & Johnson's GNG2,113 show promise in treating chronic diseases, with potential to change administration methods and improve patient compliance [3][17][20][27]. Financial Performance and Projections - **Kanglong Chemical**: Expected adjusted net profit of 2.12 billion yuan by 2026, with a price-to-earnings ratio of 25 times [11]. - **ProPharma**: Anticipated to see a compound annual growth rate exceeding 20% by 2027, with a current P/E ratio of about 14 times [11]. - **Tianyu Co.**: Projected profit of 300 million yuan for the year, with a growth rate of over 30% expected [14]. Challenges and Considerations - **Regulatory and Market Dynamics**: The medical device sector faces pressures from policy changes and international competition, necessitating innovation and adaptation [5][6]. - **Blood Product Supply**: The industry is experiencing a supply-demand imbalance, with potential for improvement as new products are introduced [12][15][16]. - **Oral Peptide Development**: Challenges in molecular modification and large-scale production remain significant hurdles for the commercialization of new oral peptide drugs [27]. Conclusion - The pharmaceutical and medical device industries are poised for growth, with several companies showing strong potential for recovery and innovation. Investors are encouraged to focus on key players within these sectors, particularly those involved in innovative drug development and high-value medical devices, as they navigate the evolving market landscape [1][4][5][11][14].

Core Viewpoint - The CXO sector in the A-share market is experiencing significant growth, with 20 out of 29 listed companies reporting year-on-year revenue increases in the first three quarters, driven by internationalization and policy support for innovative drug companies [1][2]. Group 1: Industry Trends - Three major trends are emerging in the innovative drug sector: 1. Deepening internationalization 2.0, with an expected 103 license-out transactions and a record upfront payment of $8.45 billion by 2025, leading to valuation premiums for companies going abroad [2]. 2. Unprecedented policy support, including improved efficiency in medical insurance negotiations and the establishment of a commercial insurance directory for innovative drugs [2]. 3. Continuous technological breakthroughs, with advancements in ADC, IO dual antibodies, GLP-1 weight loss drugs, and small nucleic acid drugs [2]. Group 2: Market Outlook - The CXO industry adjustment is largely complete, with stable overseas demand and a rebound in domestic investment and financing, particularly for CDMO companies with strong international capabilities and leading clinical CROs [2]. - The recovery of the upstream industry chain is significant, with ample room for increasing domestic production rates, driven by smart and digital production alongside international expansion [2]. - The capital market's recovery in financing activities and the expansion of innovative drug transactions abroad, combined with a potential recovery in domestic innovative drug R&D demand, are expected to boost CXO companies' performance in the second half of the year [1]. Group 3: Key Companies - Leading companies in the CXO sector include: - Kelaiying (06821) - Kanglong Chemical (03759) - Zhaoyan New Drug (06127) - WuXi Biologics (02269) - WuXi AppTec (02359) [3].

Core Viewpoint - Multiple oral cyclic peptide drugs have significant potential, and the industry chain is expected to benefit fully from this development [11][18]. Market Review - The CITIC pharmaceutical index decreased by 6.76%, underperforming the CSI 300 index by 2.99 percentage points, ranking 25th among 30 primary industries [7]. - The top ten stocks by increase this week include Hainan Haiyao, *ST Changyao, and *ST Suwu, while the top ten stocks by decrease include Jindike and Haichen Pharmaceutical [7][8]. Overall Viewpoint and Investment Themes - **Innovative Drugs**: The domestic innovative drug industry is transitioning from quantity logic to quality logic, emphasizing products that can ultimately generate profits. By 2025, more attention should be paid to differentiated domestic products and international pipelines [9]. - **Medical Devices**: The bidding volume for imaging equipment has significantly rebounded this year, and home medical device markets are benefiting from subsidy policies. The orthopedic sector is expected to see good growth post-collection [9]. - **Innovation Chain (CXO + Life Science Services)**: Overseas investment and financing are expected to continue recovering, while domestic financing is likely to stabilize. The innovation chain wave is anticipated to begin a bottom reversal [9]. - **Pharmaceutical Industry**: The specialty raw material drug sector is expected to see cost improvements, leading to a new growth cycle. Attention should be paid to new volumes from patent expirations and the gradual realization of formulation expansions [10]. Focus on Oral Cyclic Peptide Drugs - **Oral PCSK9 Inhibitors**: These drugs are expected to reshape the lipid-lowering treatment landscape. Current injectable PCSK9 inhibitors have poor patient adherence, and oral formulations could capture market share due to their convenience [11][19]. - **Clinical Data**: Recent clinical data for several oral cyclic peptide candidates in autoimmune and metabolic diseases have shown positive results, indicating a promising future for these therapies [13][19]. Focus on Oral IL-23 Antagonists - **JNJ-2113**: This oral peptide antagonist has shown positive Phase III data and has been submitted for FDA approval. It demonstrates significant efficacy in treating psoriasis, with high response rates compared to existing therapies [28][34]. - **Market Potential**: The annual peak sales for JNJ-2113 across all indications (psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease) are expected to exceed $5 billion [41]. Industry Chain Benefits - Companies involved in the research and production of cyclic peptides are expected to benefit significantly. Notable domestic CXO companies include WuXi AppTec, Kanglong Chemical, and Kelaiying, with projected growth in net profits and market capitalization [42].